Date: 2026-02-22 Quarter: Q3 FY26 (ended Oct 31, 2025) Analyst: wsm007 Position: Long RBRK 7.2% + LEAPS Jan'27 $85C 4.4%
Strong quarter, but the market is confused by material rights noise. Strip that out and you have a 35% normalized grower with 80%+ gross margins, a record net new ARR quarter ($94M), and an extraordinary FCF inflection (22% margin). The leading indicators are diverging bullishly from reported revenue — that's the alpha signal. My concern is the NRR flatline at 120% for five consecutive quarters. If that cracks below 120%, I'm out. The March 12 Q4 print + FY27 initial guide is the real test. Thesis: Intact.
| Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26* | |
|---|---|---|---|---|---|---|---|---|---|
| Period | Jan-24 | Apr-24 | Jul-24 | Oct-24 | Jan-25 | Apr-25 | Jul-25 | Oct-25 | Jan-26 |
| Revenue ($M) | 159.0 | 172.2 | 191.0 | 221.5 | 244.0 | 265.7 | 297.0 | 350.2 | 342.0 |
| QoQ % | +10.9% | +8.3% | +10.9% | +16.0% | +10.2% | +8.9% | +11.8% | +13.1% | -2.3% |
| YoY % | +6.3% | +58.9% | +49.8% | +54.5% | +53.5% | +54.3% | +55.5% | +48.3% | +33.0% |
| Gross Margin [GAAP] | 77.1% | 48.7% | 73.1% | 76.2% | 77.3% | 80.5% | 79.4% | 80.5% | — |
| Op Margin [GAAP] | -47.5% | -3.9% | -82.1% | -52.8% | -45.0% | -33.4% | -30.5% | -21.6% | — |
| FCF ($M) | 8.7 | — | -32.0 | 15.6 | 75.2 | — | 57.5 | 76.9 | — |
| FCF Margin | 5.0% | — | -15.6% | 6.6% | 29.1% | — | 18.6% | 22.0% | — |
| Sub ARR ($B) | 0.784 | 0.856 | 0.919 | 1.002 | 1.093 | 1.181 | 1.252 | 1.347 | ~1.443 |
| Net New ARR ($M) | 59 | 72 | 63 | 83 | 91 | 88 | 71 | 94 | ~96 |
| Cloud ARR ($B) | — | 0.606 | 0.678 | 0.769 | 0.876 | 0.972 | 1.064 | 1.175 | — |
| Cloud % of Sub ARR | — | 70.7% | 73.8% | 76.7% | 80.1% | 82.3% | 84.9% | 87.2% | — |
| $100K+ Customers | 1,742 | 1,859 | 1,969 | 2,085 | 2,246 | 2,381 | 2,505 | 2,638 | ~2,780 |
| NRR | 1.33 | 1.30 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | 1.20 | — |
Q4 FY26: Revenue prelim disclosed during Q3 call. ARR = midpoint of 1, 439 − 1, 453Mguide.OfficialresultsMarch12, 2026. * *Note : Q1FY25GAAPmarginsdistortedbyIPO − relatedSBCcharges( 700M+). Ignore.
The reported YoY numbers (48% → guided 33%) look like deceleration. They are — but mostly artificial. The material rights revenue (~$68M in FY26, non-recurring) inflated Q1-Q3 reported YoY numbers and now falls away in Q4. Normalized growth is ~35% throughout.
More telling: the QoQ pattern. Prior Q4s were +10.9% (FY24) and +10.2% (FY25). Q4 FY26 guides to -2.3% sequentially. That's the first sequential decline in this data set. Partially explained by material rights normalization, partially by conservatism. I'll know more on March 12.
The comparison frame I care about: Q3 QoQ of +13.1% vs. Q3 FY25 (+16.0%) and Q3 FY24 (+12.5%). Slightly below prior year's exceptional Q3 but above the year before. Not alarming.
Revenue trajectory: Decelerating (reported). Stable (normalized). → Ambiguous until March 12.
This is where it gets interesting. While reported revenue shows deceleration, the actual leading indicators are accelerating:
Net New Subscription ARR:
Q3 FY25: $83M
Q4 FY25: $91M
Q1 FY26: $88M
Q2 FY26: $71M ← dip (seasonal)
Q3 FY26: $94M ← record
Q4 FY26 implied: ~$96M (midpoint of ARR guide)Net new ARR is the true demand signal. It's accelerating off the Q2 dip. A record 94MinQ3followedbyanimplied 96M in Q4 suggests the bookings engine is healthy.
$1M+ Customer Adds:
Cloud ARR growth vs. Subscription ARR growth:
Security products as % of NRR: 40% (up from 32% YoY). Cross-sell is working even if NRR headline is flat.
→ Leading indicators diverging bullishly from reported revenue. This is the alpha signal my framework looks for.
Five consecutive quarters at exactly ">120%". This is the one thing that bothers me.
NRR trajectory:
Q2 FY25: 1.49 → Q2 FY25: 1.46 → Q3 FY24: 1.40 → Q4 FY24: 1.33 → Q1 FY25: 1.30 → Q2 FY25: 1.20 → Q3 FY25: 1.20 → Q4 FY25: 1.20 → Q1 FY26: 1.20 → Q2 FY26: 1.20 → Q3 FY26: 1.20The deceleration from 1.49 to 1.20 was brutal. It has now stabilized. The question: does it re-accelerate as identity and AI Ops products drive more expansion? At $20M ARR, identity is still immaterial. If NRR stays at 120% for another 4-6 quarters while identity scales, I'd call that a holding pattern. If NRR drops below 120%, expansion is contracting and I'd reassess.
For now: NRR flatline is a concern, not a thesis-breaker. Watch it.
This is the most underappreciated aspect of Q3 FY26:
Operating margin [GAAP]: -21.6% vs. -52.8% in Q3 FY25. A 31pp swing in one year. Structural improvement, not one-time.
First non-GAAP profitable quarter in company history: $10.1M operating income.
FCF: $76.9M in Q3 alone. FCF margin of 22%. Full-year guide was 194 − 202M.Q1 − Q3cumulativeisalready 212M (per guidance.md). So management is guiding to near-zero or negative Q4 FCF, which seems highly conservative given Q4 FY25 was $75.2M. Either very conservative or there's a Q4 cash timing item I'm not seeing.
→ FCF guidance is almost certainly sandbagged. Full-year FCF of $250M+ is achievable.
| Metric | Value | Assessment |
|---|---|---|
| Market cap | ~$10.9B | — |
| Run-rate revenue (Q3 × 4) | $1,401M | — |
| Run-rate P/S | 7.8x | Cheap for 35% grower |
| Run-rate FCF (Q3 × 4) | $308M | — |
| Run-rate P/FCF | 35x | Reasonable |
| Sub ARR | $1,347M | — |
| EV/ARR | ~8.1x | Cheap vs. peers |
Never TTM, never forward. Just what the business is doing right now.
Peer context (Jamin Ball territory): CrowdStrike trades at ~15x EV/TTM revenue at ~25% growth. RBRK at 7.8x run-rate P/S at 35% normalized growth is materially cheaper on a growth-adjusted basis. PEG-equivalent: RBRK 0.22x vs. CRWD 0.60x. The market is pricing in significant further deceleration.
The market is wrong if 30%+ ARR growth sustains into FY27 and FCF approaches $300M.
Prior beliefs (pre-Q3): [No prior WSM analysis of RBRK exists. Starting fresh.]
Thesis going in: I've been holding 7.2% + LEAPS since before this analysis. The core thesis is cloud-native displacement of legacy backup/recovery vendors, with identity and AI Ops expanding the TAM into CISO budgets. At sub-10x revenue for a 35% grower, the valuation had compressed to a reasonable entry point.
Updated beliefs after Q3:
| Item | Prior | Updated |
|---|---|---|
| Revenue trajectory | Decelerating on material rights distortion | Confirmed — normalized ~35% stable |
| FCF inflection | Expected, timeline uncertain | Better than expected — $212M YTD vs $198M full-year guide |
| NRR | Concerned about flatline | Still concerned. 5 quarters at 120%. Watch. |
| Identity/AI Ops | Promising but immaterial | $20M ARR, customer count doubling. Still early. |
| Q4 FY27 guide risk | Key unknown | March 12 is the moment of truth |
| Dilution | High but IPO-related | Declining as % of revenue. Manageable path forward. |
Atlas gave conviction 3.5/5. I'd go 4/5. The difference:
FCF is more important than Atlas weighted. Q1-Q3 at $212M vs. $198M full-year guide isn't just "guidance sandbagging" — it means the cash generation story is compressing years of skepticism. At 35x run-rate P/FCF, growth-oriented income investors should be paying attention.
Net new ARR acceleration is underweighted. Record $94M in Q3 → implied $96M in Q4. These are bookings, not recognized revenue. They show up in revenue 12-18 months later. The leading indicator is pointing up.
Atlas correctly identifies the Q4 sequential decline as anomalous. I agree. The -2.3% QoQ vs. historical +10% is odd and needs explanation on March 12.
The LEAPS ($85C Jan'27) are aggressive. Stock needs to nearly double from 50tomaketheseworthwhile.Thatrequiresthemarkettorepriceto 12 − 13xrun − rateonFY27guide.PossibleifFY27normalizedguideis > 30280M. Not guaranteed.
| Metric | Bull Case | Bear Case | My Base |
|---|---|---|---|
| Q4 revenue | $342M (within guide) | <$341M | $342M ✓ (prelim disclosed) |
| FY27 sub ARR guide | >$1.9B (+32%+) | <$1.75B (<22%) | ~$1.85-1.9B |
| FY27 normalized rev growth | >30% | <25% | ~28-32% |
| FY27 FCF guide | >$280M | <$200M | ~$250-280M |
| NRR | Improving to >120% | Declining to ~115% | Stable >120% |
| Net new ARR Q4 | >$96M | <$85M | ~$96M |
**If FY27 guide is 30%+ normalized revenue growth + 280M + FCFguidance → stockre − rates. * *At12xrun − raterevenueon 480M quarterly run-rate, market cap would be ~$23B vs. $10.9B today. That's where the LEAPS start working.
| Risk | Probability | Impact | Monitoring |
|---|---|---|---|
| NRR drops below 120% | Medium | High | Per-quarter. Immediate thesis review. |
| FY27 normalized guide <25% | Low-Medium | High | March 12 catalyst |
| SBC stays >20% of revenue | Medium | Medium | Q-by-Q — must trend down |
| Cohesity-Veritas IPO disrupts market | Low-Medium | Medium | Track their ARR growth |
| Q4 sequential revenue decline vs. prior seasonality | Already happened | Watching for explanation | March 12 |
Rubrik delivered the best FCF quarter in company history, record net new ARR, and first-ever non-GAAP profitability. The reported revenue deceleration (48% → 33%) is largely material rights normalization, not fundamental weakening. At 7.8x run-rate P/S for a 35% normalized grower with 80%+ GM and a rapidly expanding FCF profile, the valuation is cheap relative to peers.
Thesis: Intact. Action: Hold. Watch March 12 closely. Add if FY27 guide is strong and NRR holds.
The LEAPS ($85C Jan'27) require near-stock-doubling — that's a high hurdle. They survive only if March 12 delivers a strong FY27 guide that causes multiple expansion. Not cutting them pre-catalyst.
One thing nagging: five quarters of exactly ">120%" NRR, with no precision. Management is clearly managing the disclosure here. I want to see this break out — either explicit improvement or I trim.
-wsm
(Long RBRK 7.2%, LEAPS Jan'27 $85C 4.4%)